Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome.
Sathyapalan, Thozhukat
Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome. [electronic resource] - Clinical endocrinology Oct 2016 - 671-3 p. digital
Publication Type: Letter; Randomized Controlled Trial
1365-2265
10.1111/cen.13120 doi
Body Mass Index
Cannabinoid Receptor Antagonists--therapeutic use
Cytokines--blood
Female
Hepatocyte Growth Factor--blood
Humans
Hypoglycemic Agents--therapeutic use
Insulin--therapeutic use
Insulin Resistance
Metformin--therapeutic use
Non-alcoholic Fatty Liver Disease--blood
Obesity--blood
Piperidines--therapeutic use
Polycystic Ovary Syndrome--blood
Pyrazoles--therapeutic use
Rimonabant
Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome. [electronic resource] - Clinical endocrinology Oct 2016 - 671-3 p. digital
Publication Type: Letter; Randomized Controlled Trial
1365-2265
10.1111/cen.13120 doi
Body Mass Index
Cannabinoid Receptor Antagonists--therapeutic use
Cytokines--blood
Female
Hepatocyte Growth Factor--blood
Humans
Hypoglycemic Agents--therapeutic use
Insulin--therapeutic use
Insulin Resistance
Metformin--therapeutic use
Non-alcoholic Fatty Liver Disease--blood
Obesity--blood
Piperidines--therapeutic use
Polycystic Ovary Syndrome--blood
Pyrazoles--therapeutic use
Rimonabant